1. DeFrancesco, L. Nat. Biotechnol. 32, 8 (2014 human beings and inventions that use human embryos for commercial purposes. The Directive does not explicitly prohibit patents on PGD methods 13 . Because US patent law does not require that inventions satisfy a morality condition, it is unlikely the courts will invalidate 23andMe's (Mountain View, CA, USA) patent on moral grounds. It remains to be seen how European courts will deal with patents on PGD processes. The debate about the patentability of human embryonic stem (hES) cells could foreshadow how European countries and the United States will address these issues. Although the United States continues to recognize patents on hES cells as valid, the European Court of Justice, which has jurisdiction over members of the EU, has ruled that inventions involving the destruction of human embryos cannot be patented because they offend public morality. Stem cell lines created by methods that do not involve the destruction of embryos might be patentable, however 14 . It is conceivable that the EU could declare PGD patents invalid on moral grounds.
In thinking about the moral and policy issues related to 23andMe's patent, it is important to appreciate three pertinent facts. First, PGD occurred long before the patent was issued and will continue to occur regardless of whether any methods of testing and selecting embryos are patented. Rejecting PGD patents on moral grounds is not likely to stop 23andMe or other companies from developing this reproductive technology.
Second, PGD is legal in the United States and many other countries. Some countries, including Australia, the UK and Germany, regulate PGD. The UK's Human Fertilisation and Embryology Authority (London) licenses fertility specialists to perform PGD for 280 genetic conditions 15 .
Third, the process patented by 23andMe can be used for a good purpose (i.e., to predict disease susceptibility). Many patented inventions have good and bad uses. Rejecting a patent because an invention could be used for bad or ethically questionable purposes is like throwing the baby out with the bath water. Some couples that learn the sex of their child through ultrasound imaging decide to abort children of an unwanted sex 16 . Although selective abortion based on sex is ethically questionable because it is a form of sexual discrimination that skews the sex ratio, it would be imprudent to refuse to grant patents for sonogram machines on the grounds that they could be used to inform decisions leading to selective abortion based on sex. The wisest course of action is to grant these patents but take steps to regulate the practice of selective abortion to avoid sexual discrimination. Likewise, in the case of 23andMe's invented process, the most reasonable policy is to grant the patent but take steps to regulate PGD to avoid designer babies and other ethical problems related to this technology.
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Putting cells to sleep for future science
To the Editor: Central to the delivery of biotechnological and biomedical products is the ability to preserve and store biological reagents and materials with guaranteed genetic and phenotypic stability. This is vital to secure starting materials, reproducibility of manufacturing processes, consistency of the result or product and requirements for patent deposits. Although freeze-drying (lyophilization) may be used to stabilize some biological materials, including many strains of bacteria and fungi, it cannot guarantee indefinite viability and maintenance of sample quality. Cryopreservation (preservation in an aqueous state) is widely assumed to provide the answer to the question of how best to maintain master stocks of cell lines and other biological materials, but this is often a matter of faith rather than the application of qualified technology. Here we explore the current state of the 'art' , with an emphasis on where research and training is urgently needed to ensure the necessary skills are maintained and to assure the applicability, efficacy and sustainability of this important technology.
Storage at ultra-low temperatures effectively places cells in suspended animation. Assuming the thermal stability of the system used to store the cells is maintained below a critical temperature (that is, glass-transition temperature that is typically around -130 °C), the 'shelf-life' of stored specimens may be theoretically decades, if not hundreds of years. However, the approaches used to develop cryopreservation protocols are typically empirical and do not match the sophistication of current '-omics' analytical systems, for example. These new technologies offer the prospect of bringing an unprecedented level of scientific scrutiny to sample characterization and integrity before and after storage.
In addition, parameters for preservation methods, critical storage temperature and recovery vary with the cell type, the medium in which they are preserved and the preservation technique used. There is rarely any substantial degree of assurance that material recovered, as live cultures in the future, will have conserved the properties of the original cells. Furthermore-contrary to common scientific belief-many taxa and cell lines with biotechnological potential are recalcitrant to current cryopreservation procedures and either do not survive, have unacceptably low levels of survival or may lose critical characteristics that are difficult to measure. Developing new biotechnological for the quality of research data and suggest there is a substantial risk to scientific development associated with the status quo where many key materials cannot be cryopreserved or their post-preservation performance cannot be assured.
Worse still, these issues have been compounded by the decline of cryobiology as a scientific discipline in its own right. Most life scientists do not have any experience of cryobiology, and this is a major gap in our competency for future research and development. Expert knowledge in this area is limited to a very few centers in most countries, and thus the ability to anticipate and resolve emerging challenges in cryopreservation is in decline. This has meant that where cryobiology research is funded it is not always coordinated with, and supported by, the best national expertise.
As we have already indicated, most scientists use preservation methods as tools to conserve their materials with limited knowledge regarding the suitability, or efficacy, of the method used. 'Re-growth' is commonly accepted as indicative of the success and suitability of the protocol used without consideration for the potential loss of key components or activities. Most methodological developments in the field have depended on empirical approaches, and although this has had some success, as already discussed, there are clear limitations. Few recent large R&D projects have been focused on fundamental innovations in cryoscience; notable exceptions include Cryostar EC and COST Action 871, CRYOPLANET (the European Cooperation in Science and Technology Action 871 for conservation of crop species in Europe), conservation of algae (COBRA) 15 and stem-cell preservation for research and clinical application (CRYSTAL). Although these have generated much knowledge and built linkages within the scientific community, in most cases, they have not closely coordinated biological resource centers and fundamental cryobiological research with mammalian, plant and microbial research communities. This situation is now causing damage to our scientific base where lack of fundamental understanding inevitably leads to proliferation of bad practice, poor training and inability to troubleshoot failing processes effectively.
Finally, even when substantial collections of valuable preserved material are established, there is little consideration for long-term sustained storage, and funding is usually constrained within standard research funding cycles, which will not sustain precious research materials for the future. Increasingly, grant types of stem cells and neutrophils for human therapy, as well as the influenza virus); more worrying, there is a lack of knowledge of the scientific principles underpinning cryobiology among life scientists. Given the increasing importance of preservation technology in the modern world, a clear need exists to have reliable methodologies as well as strong research and development activity in cryobiology to ensure that new products and applications are fit for purpose.
A key component for testing predictions from genetic and in silico omics analyses will be the availability of demonstrably pure preparations of the original cells in which to test those predictions. At the moment, however, when a researcher submits a cell culture (prokaryotic or eukaryotic) to a preservation process in the laboratory, the approach is typically empirical (often copying a method used for some other organism), and there is no attempt to provide an adequately qualified reference stock of material to serve the increasingly sophisticated omics analytical systems for characterizing the sample. Thus, there is often a lack of assurance that samples recovered by researchers in the future will have conserved the properties of the original cells. Greater attention is needed to three aspects. First, stability-typically measured by genetic analysis of recovered cells, although it could be related to other parameters, including epigenetic markers and functional assays (at present, in most cases no analyses of this type are performed). Second, viability-each method used to assess viability measures a particular aspect of cell biology and different methods can yield different results for the same culture 10 . And third, culture conditions and the quality of reagents used to recover cells.
For a particular organism or cell type, there are often numerous reports of the successful application of cryopreservation based on viability assays, but relatively few of these conclusively demonstrate the recovered culture to be identical to the original cells. In many microbial applications, regeneration of fresh cultures from cryopreserved samples with low levels of post-thaw viability is accepted (e.g., viral recoveries often have a log reduction in infectious particles), but this runs inherent risks, including possible selection of a cryo-tolerant subpopulation. Additionally, there are well-documented examples of failure of preservation methods for eukaryotic cells and the tissues they comprise, such as bonemarrow transplant material 11 . Furthermore, a small number of studies report post-thaw genotypic 12 and phenotypic anomalies 13, 14 . Such observations have profound implications approaches capable of exploiting the potential of protists (including algae), animal cell lines and other biological materials without being able to ensure their stability and security is clearly a very high-risk strategy.
Two principal issues stymie progress in cryopreservation: a general lack of fundamental understanding of cryobiological processes among life scientists, and lack of successful protocols for key organisms and cells. Since the pioneering work of Polge et al. 1 on the application of glycerol as a cryoprotectant to preserve avian spermatozoa, three conceptually different preservation technologies have been developed-namely, colligative cryopreservation, vitrification and lyophilization (see ref. 2 for reviews). In addition, cryopreservation as a scientific discipline has been crucial for a diverse range of improvements for human health and economic wealth. Cryobiology has influenced processes ranging from the ancient art of brewing to ground-breaking medical treatments 2 . Landmark successes with cryobiology at their core include the following: first, the use of industrial-scale preservation of spermatozoa, ova and fertilized eggs in selective-breeding programs to increase dairy and meat yield in cattle 3 ; second, the development of routine procedures to conserve gametes and fertilized embryos to aid human fertility treatment; and third, the application of cryobiology to enable widespread use, distribution and long-term, stable storage of novel biotech products, including transgenic algae, live viral vaccines, and biosynthetic organisms with wide ranging, yet-unfathomed potential function [4] [5] [6] . Cryobiology has also contributed towards assuring the safety and efficacy of a wide range of medicines through the availability of preserved reference preparations for product standardization and control 7, 8 , and it has optimized preservation technologies such as vitrification to potentially improve benefits from donated organs and the affordability of a rapidly increasing range of cell therapies (4,749 cell-therapy clinical trials identified in January 2013, ref. 9), many of which will benefit from long shelf lives and thorough safety testing permitted by use of biopreservation techniques. Finally, advances in cryobiology have enabled the conservation of critical germplasm collections (e.g., the frozen zoo; http://www.sandiegozooglobal.org/) to aid efforts to protect biodiversity.
However, too often, current preservation protocols are not successful for biological materials and organisms important for research and in applications (e.g., lipidproducing Prymnesiophytes algae, certain recovered cells, improved integration of omic data and cells, better scientific standardization, and assurance of cell batches for therapy and sound foundations for future biotechnology. disciplinary research. Such work would be fully compatible with recent international reports calling for infrastructure support for biobanks 17 , the ESFRI Roadmap (http:// ec.europa.eu/research/infrastructures/ index_en.cfm?pg=esfri-roadmap) and truly innovative research into fundamental cryobiological issues (ISBER, http://www.isber. org/).
In addition to the above, it is vital for research funders to be proactive in two main respects. First, they should recognize the training and education gap in cryobiology and promote initiatives to facilitate the kinds of cross-fertilization described above. And second, they should encourage greater strategic planning to identify potential key collections of research materials and secure both their long-term storage, possibly through national storage facilities such as the UK BioBank.
Clearly, committing precious viable material into the freezer using a limited number of proven methods is likely to result in the loss of key research materials, and can also lead to the generation of misleading data from preservation-mediated alterations to genotype and phenotype. There are major constraints to scientific development associated with continuing with the status quo, where many key materials cannot be cryopreserved or their post-preservation performance cannot be assured. Appropriate targeted investment, both in fundamental studies and in protocol development for materials with predicted biomedical or biotechnological potential, is likely to have major benefits. These benefits could include greater predictability of application processes require plans for the use of biological resource(s) developed during the project, and these plans should take into account conservation of the resources, but this idea is difficult to implement as the output of conservation often does not seem commercially attractive. Funds are rarely specifically allocated to the long-term conservation of the materials generated in a project and sustainability of centrally collected material suffers from an ongoing tendency for academic researchers to engage in informal exchange of these materials, which are also known to increase the likelihood of errors sufficiently grave to result in retraction of published research findings 16 .
Going forward, it will be important for anyone starting to work on preservation techniques to access specialist cryobiological expertise via expert scientific societies, such as the Society for Cryobiology (http://www. societyforcryobiology.org/), the Society for Low Temperature Biology (SLTB) (http:// www.sltb.info/) and the International Institute of Refrigeration (http://www.iifiir.org/). These organizations represent a focus of established cryo-related experience and are keen to engage newcomers who wish to take cryobiology forward in new areas building on a strong history of cryobiological research. These groups also provide important fora for scientific cross-fertilization of ideas and interdisciplinary translation. We suggest that future investment in this area should be targeted at more efficient transfer of cryobiological scientific principles and technological developments with particular emphasis on the importance of cross-
